New animal study shows promise for development of Parkinson's disease drug

Published in inaugural issue of the Journal of Parkinson's Disease

2011-06-10

(Press-News.org) Amsterdam, NL, 9 June 2011 – Few treatments for Parkinson's disease (PD) restore function for extended periods. In a new study published today in the inaugural issue issue of the Journal of Parkinson's Disease, an international group of researchers report that platelet-derived growth factor-BB (PDGF-BB) restored function in rodents and shows promise as a clinical candidate drug for treatment of PD.

Parkinson's disease is the second most common neurodegenerative disorder, affecting 1𔃀% of the population over the age of 65. It is characterized by loss of brain cells (neurons) from the mid-brain which use the neurotransmitter dopamine to help control voluntary movements. Investigators from NeuroNova AB, Stockholm, Sweden, the Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden, The Parkinson's Institute, Sunnyvale, CA, USA, and Motac Neuroscience Ltd, Manchester, UK, found that behavioral, tissue and biochemical changes in experimental models of Parkinson's disease in rodents could be counteracted by infusion of PDGF-BB. This could offer an alternative strategy to restore function in PD.

"In animal models of nigrostriatal injury, a two weeks treatment with platelet-derived growth factor-BB resulted in long-lasting restoration of striatal dopamine transporter binding sites and expression of nigral tyrosine hydroxylase," commented Anders Haegerstrand, MD, PhD, Chief Scientific Officer, NeuroNova AB, Stockholm, Sweden."It also normalized amphetamine-induced rotational behavior in 6-hydroxydopamine lesioned rats. Platelet-derived growth factor-BB promoted proliferation of neural progenitor cells in the subventricular zone. The effects on dopaminergic neurons and functional recovery could be blocked by co-infusion with a proliferation inhibitor, indicating a link between the proliferative and anti-parkinsonian effects. Based on the current data, we consider platelet-derived growth factor-BB a clinical candidate drug for treatment of Parkinson's disease."

### The study demonstrated for the first time a functional relevance of a PDGF-induced cell proliferation in a model of CNS disease. In the rats studied, normalization of behavior after PDGF-BB treatment lasted for 10 weeks. PDGF-BB is already in clinical trial at NeuroNova (www.neuronova.com/index.php?option=com_content&task=view&id=41&Itemid=72).

The article is "Restorative Effects of Platelet Derived Growth Factor-BB in Rodent Models of Parkinson's Disease" by Olof Zachrisson, Ming Zhao, Annica Andersson, Karin Dannaeus, Johan Häggblad, Ruben Isacson, Elisabet Nielsen, Cesare Patrone, Harriet Rönnholm, Lilian Wikstrom, Kristofer Delfani, Alison L. McCormack, Theo Palmer, Donato A. Di Monte, Michael P. Hill, Ann Marie Janson Lang, and Anders Haegerstrand. Journal of Parkinson's Disease. 1(1). DOI 10.3233/JPD-2011-0003. Published by IOS Press.

ELSE PRESS RELEASES FROM THIS DATE:

New method for measuring Parkinson's disease prevalence reveals sharp increase in Israel

2011-06-10

Amsterdam, NL, 9 June 2011 – In a new study published today in the inaugural issue of the Journal of Parkinson's Disease, Israeli researchers report that by tracking pharmacy purchases of anti-Parkinson drugs they could estimate the number of Parkinson's disease (PD) cases in a large population. The study identified a sharp rise in PD prevalence from 170/100,000 in 2000 to 256/100,000 in 2007 in Israel, which warrants further investigation. Surprisingly, much of the world lacks accurate figures for the percentage of the population (prevalence) with PD and the rate of ...

Chemistry with sunlight

2011-06-10

The idea is simple, says Kevin Moeller, PhD, and yet it has huge implications. All we are recommending is using photovoltaic cells (clean energy) to power electrochemical reactions (clean chemistry). Moeller is the first to admit this isn't new science. "But we hope to change the way people do this kind of chemistry by making a connection for them between two existing technologies," he says. To underscore the simplicity of the idea, Moeller and his co-authors used a $6 solar cell sold on the Internet and intended to power toy cars to run reactions described in an article ...

Confused.com Reveals 56% of Drivers Forget Where They Park

2011-06-10

Confused.com has revealed that 56% of UK drivers have at some point, forgotten where they have parked their car, and 3% have picked up the phone to ask their breakdown service to help them find it. More than 50 in 2,000 drivers in the UK admit to making that call according to a new survey by car insurance comparison site Confused.com. The Confused.com survey has revealed some of the gaffes of UK drivers, which have led them to phone for their breakdown service, like 25% of drivers have locked their keys in the car and 10% of drivers have had to call for their breakdown ...

Landmark study analyzes scientific productivity and impact of the top 100 PD investigators

2011-06-10

Amsterdam, NL, June 9, 2011 – IOS Press is pleased to announce the publication of a landmark study in which both traditional and innovative scientometric approaches have been employed to identify the top 100 Parkinson's disease (PD) investigators since 1985 and measure their scientific productivity as well as the impact of their contributions to the field. The article appears today in the inaugural issue of the Journal of Parkinson's Disease. This milestone analysis has been conducted by Aaron A. Sorensen, a noted expert in the fields of scientometrics and bibliometrics ...

Mayo Clinic-led research team tests alternative approach to treating diabetes

2011-06-10

JACKSONVILLE, Fla. — In a mouse study, scientists at Mayo Clinic Florida have demonstrated the feasibility of a promising new strategy for treating human type 2 diabetes, which affects more than 200 million people worldwide. In type 2 diabetes, the body stops responding efficiently to insulin, a hormone that controls blood sugar. To compensate for the insensitivity to insulin, many diabetes drugs work by boosting insulin levels; for example, by injecting more insulin or by increasing the amount of insulin secreted from the pancreas. The new study, published in the ...

Executive Healthcare Provider EliteHealth Selected by Holman Auto's Executive Team

2011-06-10

A leading provider of executive health and corporate health programs, concierge medical service EliteHealth has been selected by the southern division of Holman Automotive Group - one of the nation's top auto dealership and leasing companies - to provide a Wellness Program for their managerial staff. The move follows a successful implementation of EliteHealth's Executive Wellness Program in 2010, which has provided concierge medical services to 15 of Holman's southern executive management group. More and more companies are recognizing that corporate success is dependent ...

Cancer protein discovery may aid radiation therapy

2011-06-10

BOSTON--Scientists at Dana-Farber Cancer Institute have uncovered a new role for a key cancer protein, a finding that could pave the way for more-effective radiation treatment of a variety of tumors. Many cancers are driven in part by elevated levels of cyclin D1, which allow the cells to escape growth controls and proliferate abnormally. In the new research, reported in the June 9 issue of Nature, researchers discovered that cyclin D1 also helps cancer cells to quickly repair DNA damage caused by radiation treatments, making the tumors resistant to the therapy. Based ...

Penn researchers show new evidence of genetic 'arms race' against malaria

2011-06-10

PHILADELPHIA — For tens of thousands of years, the genomes of malaria parasites and humans have been at war with one another. Now, University of Pennsylvania geneticists, in collaboration with an international team of scientists, have developed a new picture of one way that the human genome has fought back. The international team was led by Sarah Tishkoff, a Penn Integrates Knowledge professor with appointments in the genetics department in Penn's Perelman School of Medicine and the biology department of biology in the School of Arts and Sciences, and Wen-Ya Ko, a postdoctoral ...

Physician participation in lethal injection executions should not be banned, argue 2 ethicists

2011-06-10

(Garrison, NY) Should physicians be banned from assisting in a lethal injection execution, or lose professional certification for doing so? A recent ruling by the American Board of Anesthesiology will revoke certification of anesthesiologists who participate in capital punishment, and other medical boards may act similarly. An article in the Hastings Center Report concludes that decertification of physicians participating in lethal injections by a professional certifying organization goes too far—though individual physicians and private medical groups like the AMA are ...

How killer immune cells avoid killing themselves

2011-06-10

After eight years of work, researchers have unearthed what has been a well-kept secret of our immune system's success. The findings published online on June 9th in Immunity, a Cell Press publication, offer an explanation for how specialized immune cells are able to kill infected or cancerous cells without killing themselves in the process. The focus of the study is a molecule known as perforin, whose job it is to open up a pore in cells targeted for destruction. With that pore in place, proteases known as granzymes can enter target cells and destroy them. Perforin ...

CMD-OPT model enables the discovery of a potent and selective RIPK2 inhibitor as preclinical candidate for the treatment of acute liver injury

Melatonin receptor 1a alleviates sleep fragmentation-aggravated testicular injury in T2DM by suppression of TAB1/TAK1 complex through FGFR1

Single-cell RNA sequencing reveals Shen-Bai-Jie-Du decoction retards colorectal tumorigenesis by regulating the TMEM131–TNF signaling pathway-mediated differentiation of immunosuppressive dendritic ce

New animal study shows promise for development of Parkinson's disease drug

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: